地舒单抗治疗对全髋关节置换术后核因子κB受体活化因子配体(RANKL)和TNF受体TNFRSF9表达的影响——一项随机安慰剂对照临床试验结果
本研究为随机安慰剂对照试验,纳入64例因髋骨关节炎行非骨水泥全髋关节置换术的患者,随机接受两剂60 mg地舒单抗或安慰剂(术后1-3天及6个月)。结果显示地舒单抗组RANKL表达显著升高、TNFRSF9降低,骨转换标志物在3、6、12个月受抑制但24个月反跳至基线以上,可能解释停药后骨密度快速丢失的反跳效应。
要点
- 地舒单抗组术后3个月RANKL血清水平为安慰剂组的2.10倍(p<0.001),6个月和12个月仍升高(比值1.50,p<0.001;1.47,p=0.002)。
- 地舒单抗组术后3个月TNFRSF9表达低于安慰剂组(比值0.68,p<0.001)。
- 地舒单抗组骨转换标志物3个月后显著降低,6和12个月持续抑制,但术后24个月升至基线以上。
核心结论
- 术后6个月间隔两次皮下注射地舒单抗可升高全髋关节置换术后RANKL并降低TNFRSF9,可能解释停药后骨转换标志物及骨密度的反跳效应。
- 其他所测炎症标志物均未受地舒单抗治疗影响。
研究设计与样本
- 随机安慰剂对照临床试验,64例因髋骨关节炎行非骨水泥全髋关节置换术的患者随机接受两剂60 mg地舒单抗或安慰剂,分别于术后1-3天和6个月给药。
- 血清样本采用多重延伸检测法分析92种炎症相关蛋白,并评估骨转换标志物,采用线性混合效应模型分析,显著发现用ELISA验证。
主要发现
- 术后3个月地舒单抗组RANKL血清水平为安慰剂组的2.10倍(p<0.001)。
- 术后6个月和12个月地舒单抗组RANKL表达仍高于安慰剂组(比值1.50,p<0.001;比值1.47,p=0.002)。
- 术后3个月地舒单抗组TNFRSF9表达低于安慰剂组(比值0.68,p<0.001)。
- 地舒单抗组骨转换标志物浓度在3个月后显著降低,6和12个月持续受抑制,但术后24个月升至基线以上。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We investigated whether the drug denosumab modulates the inflammatory response after total hip arthroplasty in a randomized controlled trial. Significantly increased expression of RANKL was found in patients treated with denosumab. This could provide an explanation for the rebound effect with rapid loss of BMD seen after discontinuation of denosumab treatment. PURPOSE: To evaluate whether denosumab, a human monoclonal antibody directed against receptor activator of nuclear factor kappa-B ligand (RANKL), modulates the inflammatory response after cementless total hip arthroplasty (THA) in patients with osteoarthritis of the hip. METHODS: Sixty-four patients operated with cementless THA were randomized to two doses of 60-mg denosumab or placebo 1-3 days and 6 months postoperatively. Serum samples were analyzed by a multiplex extension assay detecting 92 inflammation-related proteins. Bone turnover markers were assessed. Proteins were analyzed using linear mixed effect models. Validation of conspicuous findings was performed with ELISA. RESULTS: Two proteins were significantly affected by denosumab treatment: RANKL and tumor necrosis factor receptor super family member 9 (TNFRSF9). Serum levels of RANKL were more than twice as high in the denosumab than in the placebo group 3 months after surgery (ratio 2.10, p<0.001). Six and 12 months after surgery, the expression of RANKL was still elevated in the denosumab-treated group (ratios 1.50, p < 0.001; 1.47, p =0.002). The expression of TNFRSF9 was lower in the denosumab group at 3 months (ratio 0.68, p<0.001). In the denosumab group, concentrations of bone turnover markers were substantially reduced after 3 months, remained suppressed after 6 and 12 months, but increased above baseline at 24 months after surgery. CONCLUSION: Two subcutaneous denosumab injections 6 months apart increase RANKL and depress TNFRSF9 after THA. This provides a possible explanation for the rebound effect on bone turnover markers as well as bone mineral density (BMD) upon withdrawal of denosumab. None of the other measured markers of inflammation was influenced by denosumab treatment.
引用
- Sköld C, Kultima K, Freyhult E, et al. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial. Osteoporos Int. 2022. PMID: 35608639. doi:10.1007/s00198-022-06423-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。